// App-Quantinova.ai

: Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review

Researchers

Presenter

  • Jiayu Yang

Principal Investigators

  • Nora Choi

  • Lee Mozessohn

  • David Sanford

  • Kristjan Paulson

  • Donald S. Houston

  • Emily Rimmer

  • Sylvain Lother

  • Asher Mendelson

  • Allan Garland

  • Rena Buckstein

  • Annette E. Hay

  • Ryan Zarychanski

  • Brett L. Houston

Medical Centers

  • Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada

  • Department of Medical Oncology and Hematology, CancerCare Manitoba, Winnipeg, Canada

  • The Leukemia/Bone Marrow Transplant Program of British Columbia, British Columbia Cancer Agency, Vancouver, Canada

  • Department of Medicine, Queen's University, Kingston, Canada

  • Division of Hematology/Medical Oncology, Sunnybrook Health Sciences Centre, Toronto, Canada

  • University of Manitoba, Winnipeg, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelodysplastic Syndrome

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Azacitidine

  • Vidaza

  • Decitabine

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved